Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Down 35.3% in February

Pulmatrix, Inc. (NASDAQ:PULM) saw a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 2,779 shares, a decline of 35.3% from the February 12th total of 4,293 shares. Based on an average trading volume of 18,863 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 18,863 shares, the days-to-cover ratio is currently 0.1 days.

Pulmatrix Trading Down 2.3%

NASDAQ PULM traded down $0.05 during trading hours on Friday, hitting $2.11. The company’s stock had a trading volume of 10,821 shares, compared to its average volume of 52,734. Pulmatrix has a twelve month low of $1.63 and a twelve month high of $9.37. The stock has a fifty day moving average of $2.49 and a 200 day moving average of $3.74.

Pulmatrix (NASDAQ:PULM) last released its earnings results on Thursday, February 26th. The biotechnology company reported ($0.25) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On Pulmatrix

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DRW Securities LLC acquired a new position in shares of Pulmatrix during the 4th quarter worth about $46,000. Dimensional Fund Advisors LP acquired a new stake in shares of Pulmatrix in the 3rd quarter valued at approximately $52,000. Finally, SBI Securities Co. Ltd. boosted its stake in Pulmatrix by 15.7% during the 2nd quarter. SBI Securities Co. Ltd. now owns 60,565 shares of the biotechnology company’s stock worth $418,000 after acquiring an additional 8,208 shares during the last quarter. Institutional investors own 11.84% of the company’s stock.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).